Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.
Gide is physically present in six regions of the world, with 11 offices, enabling it to act on cases globally.
14 February 2024
Deals | France | FIN
Gide has advised the banking syndicate composed of Leerink Partners, Stifel and Chardan on the capital increase by Sensorion for a total gross amount of €50.5 million. Sensorion’s ordinary shares are listed for trading on Euronext Growth in Paris.
Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders. Sensorion is the most advanced european biotech with multiple genetherapy programs in the field of hearingloss.
This fundraising will finance Sensorion's R&D activities through the end of the second quarter of 2025, covering the submission of the clinical trial application of GJB2 and the first two cohorts of the Phase 1/2 Audiogene clinical trial, which was approved in Europe in January 2024.
Gide also advised the banks on Sensorion's capital increase in 2020.
The Gide team was led by partner Guilhem Richard, alongside partner Arnaud Duhamel, and comprised counsel Mariléna Gryparis and associate Shanna Kim.
Covington advised the banks on US law aspects.
Sensorion was advised by McDermott Will & Emery.
